LifeStance Health Group Inc. Common Stock vs Rambus Inc. Common Stock — how do they compare? LifeStance Health Group Inc. Common Stock trades at $12.7 (market cap $4.69B), while Rambus Inc. Common Stock trades at $90.15 (market cap $10.66B). The key difference: Rambus Inc. Common Stock is far larger — about 2.3× LifeStance Health Group Inc. Common Stock's market cap, and LifeStance Health Group Inc. Common Stock is trading nearer its 52-week high, Rambus Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold LifeStance Health Group Inc. Common Stock for 6 Days and Rambus Inc. Common Stock for 0 Days on average.
| LFST | RMBS | |
|---|---|---|
Market Cap | $4.69B | $10.66B |
Volume | 1,858,220 | 2,136,075 |
Sector | Health | Technology |
52-Week High | $13.38 | $170.66 |
52-Week Low | $4.81 | $79.73 |
Typical Hold Time | 6 Days | 0 Days |
Enterprise Value | $4.92B | $9.85B |
Signals from Pluang's Aura AI — not financial advice
LifeStance Health Group (LFST) trades at $12.32, down 1.28% today, with strong technical momentum showing a bullish moving average signal. The company has consistently beaten earnings expectations in recent quarters, with Q2 2026 EPS of $0.06 exceeding the $0.03 forecast. Revenue growth accelerated from $1.42B in 2025 to $1.6B in 2026, while net income improved significantly from $9.66M to $51M.
Wall Street maintains strong bullish sentiment with 82% buy ratings and a $14.14 consensus price target representing 15% upside. However, elevated valuation multiples (P/E 94.8) and overbought technical conditions near 52-week highs warrant caution. The mental healthcare provider benefits from industry tailwinds but faces execution risks amid competitive pressures.
Rambus (RMBS) trades at $98.17, down 2.84% over 24 hours, with a neutral technical signal and key support at $96. The company reported strong profitability with a 31.69% net income margin and beat EPS estimates in two of the last three quarters. Recent news highlights its focus on AI infrastructure with new product launches, positioning it to benefit from growing demand for high-speed memory solutions.
The outlook is positive given analyst consensus of a $161.75 price target and 78.57% buy ratings, but risks include high valuation multiples and competitive pressures. Execution on AI-driven growth and maintaining earnings momentum are critical for stock appreciation, while any miss in upcoming results could pressure the premium valuation.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
LifeStance Health provides outpatient mental healthcare, including therapy, psychiatry, and medication management services.
Read more on LFST →Rambus Inc. is a semiconductor and silicon IP company that licenses chip interface and security technologies, including memory interface chipsets for DDR5 and DDR4 server and client DIMMs, interface IP for PCIe, CXL, and HBM, and security IP such as Root of Trust and memory encryption. It serves data center, AI, automotive, and IoT markets.
Read more on RMBS →